As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

The Dublin-based firm is developing an array of artificial intelligence-derived tools to improve the efficiency of its digital pathology outsourcing service.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

NEW YORK — Tosoh Bioscience said on Thursday that it has received 510(k) clearance from the US Food and Drug Administration for its automated HLC-723 GR01 glycohemoglobin A1c (HbA1c) analyzer. The ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

The firm is projecting a gradual recovery of the academic market in the face of ongoing funding uncertainties and a government shutdown.

Called the RESULTS Act, the bill would use a third-party database to set Medicare payment rates and would delay price cuts and data reporting scheduled for 2026.

The Netherlands-based company will develop a low-cost, rapid point-of-care test using its Visualization by Infrared PEptide Reaction (VIPER) technology.

NEW YORK – Swedish infectious disease diagnostic firm Gradientech announced Thursday that its QuickMIC rapid antibiotic susceptibility testing platform has received certification under Europe's In ...